Trials / Recruiting
RecruitingNCT06602232
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
A Pilot, Safety and Clinical Activity, Phase 1b Study of DR-01 in Adults With Alopecia Areata or Vitiligo
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Dren Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DR-01 | DR-01 will be administered via IV infusion. |
Timeline
- Start date
- 2024-10-30
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2024-09-19
- Last updated
- 2025-12-11
Locations
20 sites across 3 countries: United States, Australia, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06602232. Inclusion in this directory is not an endorsement.